PARP1 and lung carcinoma: We also validated them with the listed drugs in Drugbank (Wishart et al., 2018) and TTD (Wang et al., 2020) databases and found that 179 drugs targeting core targets in lung cancer (Figure 9D), were mapped as drug-target interactions network and found that many drugs targeting genes such as EGFR, SRC, PARP1, MAPK1, and FKBP1A, among which EGFR is the epidermal growth factor receptor and high or abnormal expression of EGFR has been confirmed in many solid tumors.